This MedLibrary.org supplementary page on Actavis is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
| Type | Private |
|---|---|
| Founded | 1956 |
| Headquarters | Hafnarfjörður, Iceland |
| Key people | Sigurður Óli Ólafsson (CEO) |
| Industry | Pharmaceutical |
| Revenue | $2 billion (December 2005) |
| Employees | 11,000 |
| Website | www.actavis.com |
Actavis is an international generic pharmaceutical company founded in 1956 as Pharmaco. It is headquartered in Iceland and listed on the Icelandic Stock Exchange.
In the late 1990s, Actavis employed fewer than one hundred people and operated solely in the Icelandic market. In 1999, Actavis acquired Bulgarian rival Balkanpharma, beginning a period of substantial growth.
Since then, Actavis has made 25 acquisitions and now operates in 40 countries and employees over 11,000 people. The Group has one of the broadest portfolios in the generics sector with over 650 products on the market, in addition to over 400 products in the development pipeline and in registration.
Actavis is currently among the five largest generic pharmaceutical companies in the world. Its turnover for 2006 is predicted to be 1,390 million euros, compared to 56 million euros in 1999.
The chairman of the company is Icelandic businessman Björgólfur Thor Björgólfsson. Robert Wessman became President and CEO of Actavis following the company’s merger with Delta in 2002, where he had served as CEO since 1999. A business graduate and lecturer at the University of Iceland, Wessman worked previously at Icelandic transportation company Samskip, advancing to the post of CEO in Germany. Robert is also a Board Member of the Icelandic Chamber of Commerce.
On the 24th of November 2006, Actavis announced the departure of Svafa Gronfeldt, Deputy to the CEO. She leaves Actavis to pursue a new position as Dean of Reykjavik University. Sigurður Óli Ólafson takes her place as Deputy to the CEO. On 5th August 2008, Róbert Wessmann stepped down as the CEO to focus on his personal investments through his company, Salt Investments. Sigurður Óli Ólafsson took his place as CEO.
One noteworthy service offered by Actavis is the "Evidence-based medicine (EBM) Research Service". The service is free of charge for registered Medical Doctors (MD's) and is offered out of Austria and Switzerland. A registered MD can send a research inquiry to an Actavis team of specialists from Austrian universities, who will research the topic and provide a research report to back to the MD.
External links
Wikipedia content modification information:
- This page was last modified on 10 December 2008, at 13:36.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Actavis".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.